Indocyanine green excitation-emission matrix characterization: excitation-dependent emission shifts and application-specific spectra

Alberto J. Ruiz,[a*] **Sophie A. Lyon,**[a] **Ethan P.M. LaRochelle,**[a] **Kimberley S. Samkoe,**[b]

[a]QUEL Imaging, White River Junction, VT, USA
[b]Dartmouth Engineering, Hanover, NH, USA

Abstract

Significance: Indocyanine green (ICG) is the most widely used fluorophore in fluorescence-guided surgery (FGS), yet its spectral response depends on microenvironment, with implications for system design, inter-system comparisons, and phantom development.

Aim: To characterize ICG with excitation–emission matrices (EEMs) in the microenvironments of dimethyl sulfoxide (DMSO), bovine serum albumin (BSA) solutions, and 3D-printed (3DP) resin, and assess excitation-dependent emission, including red-edge excitation shifts (REES) and departures from Kasha's rule of excitation-independent emission.

Approach: EEMs and absorbance spectra were acquired with extracted excitation spectra, emission spectra, emission peaks, centroids, and integrated emission areas under the curve (AUCs). Concentration-dependent behavior was examined in DMSO, and albumin concentration dependence was assessed from 5–100 mg/mL. Data processing employed robust local regression to mitigate excitation scattering artifacts.

Results: ICG in DMSO exhibited excitation-independent emission consistent with Kasha–Vavilov behavior. In contrast, ICG in BSA solution and 3DP resin displayed excitation-dependent emission with pronounced REES and additional non-linear departures from Kasha's rule. To our knowledge, this represents the first documentation of REES and broader anti-Kasha effects for ICG or any FGS fluorophore. Within the excitation range most relevant to ICG-FGS (~760–805 nm), emission spectra of the BSA solution and 3DP resin overlapped closely, with similar AUC-based comparisons, suggesting that ICG in 3DP resin can serve as a suitable surrogate reference for albumin-bound ICG.

Conclusions: The EEM characterization shows that excitation-dependent behavior is a defining feature of ICG in biologically relevant environments, demonstrating that emission cannot be assumed to follow classical Kasha–Vavilov behavior. Reliable comparisons and imaging system design therefore require spectra acquired at defined excitation wavelengths with AUC integration within the emission detection band. Excitation-specific spectra from EEMs establish a consistent framework for inter-system comparisons and phantom standards, while the resulting datasets provide a practical reference for addressing excitation-dependent behavior in ICG sensing applications.

Keywords: indocyanine green (ICG), excitation-emission matrix, Excitation-dependent fluorescence, red-edge excitation shift (REES), anti-kasha fluorescence, fluorescence-guided surgery (FGS).

*Alberto J. Ruiz, E-mail: alberto@quelimaging.com

1 Introduction

Understanding the spectral characteristics of a fluorophore is crucial for fluorescence sensing,[1] including fluorescence-guided surgery (FGS).[2] The microenvironment of a fluorophore can significantly influence its physical and chemical behaviors, with factors such as local viscosity, polarity, temperature, redox conditions, and acidic-base status playing important roles.[3] In fluorescence imaging, the most relevant changes associated with the fluorophore's microenvironment are the excitation-emission spectral shifts and variations in the quantum yield,[4] since they affect the sensitivity and specificity of fluorescence sensing devices.[5–8] Among the microenvironment-sensitive spectral behaviors, solvatochromism reflects solvent-dependent differential stabilization of the ground and excited states and is observed as steady-state shifts in absorption and emission maxima.[9,10] A complementary dynamic effect is the red-edge excitation shift (REES), in which the emission spectrum becomes excitation-wavelength dependent when solvent or protein relaxation occurs on timescales comparable to or slower than the fluorescence lifetime.[11–13] This excitation dependence represents a departure from Kasha's (Kasha-Vavilov) rule,[14,15] which assumes excitation-independent emission for a given excited electronic state.[16–20] Additionally, excitation-dependents shift may be especially relevant in the complex environment of biological systems, where proteins such as serum albumin are present.[21] As FGS continues to develop, comprehensive characterization of how fluorophore spectral properties respond to physiologically relevant microenvironments can help optimize optical system design, support inter-system comparisons, and guide the development of imaging phantoms and targets that support clinical translation.[7,22,23]

Indocyanine green (ICG) is the most widely used fluorophore in FGS, utilized for tissue perfusion, cardiac flow indication, and lymph node mapping.[24–26] Its prominence in fluorescence guidance stems from its absorption and emission in the near-infrared (NIR) range, low toxicity, and extensive medical use for more than half a century.[24,25,27,28] Understanding the variability of ICG's spectral characteristics within *in vivo* environments can help optimize imaging system design and cross-system comparisons. This includes standard solvent effects as well as non-linear shifts, such as REES. Solvatochromism of ICG has been widely studied and reported. ICG shows pronounced solvatochromism: solvent polarity and binding partners modulate its absorption/emission maxima and quantum yield; albumin binding typically red-shifts and stabilizes the spectra, while aqueous self-aggregation blue-shifts absorption and quenches fluorescence.[29–34] These environment-dependent shifts have been leveraged in various applications, including human serum albumin-ICG complexes to boost tumor-to-background contrast, conjugates for targeted imaging, liposomal and J-aggregate strategies to enhance stability/brightness, and solvatochromic readouts to map solvent composition and microenvironments in situ.[35–44] Despite this extensive work on ICG solvatochromism, aggregation, and protein binding, we found no peer-reviewed reports documenting

REES or other anti-Kasha excitation-dependent effects in ICG; additionally, comprehensive spectroscopy
papers and clinical imaging reviews do not describe excitation-dependent emission consistent with REES
or with departures from Kasha's rule.[26,29–31,37,41,45–48] By contrast, REES is well established in the literature
for proteins, membranes, and protein–ligand complexes, where slow environmental relaxation relative to
the fluorescence lifetime produces excitation-dependent red-shifts that can resolve microstate
heterogeneity.[49–55] Differences in excitation–emission behavior under varying environments can be
captured by acquiring excitation–emission matrices (EEMs),[56] which provide extended spectral information
that support the assessment of solvatochromism, REES, and other microenvironmental effects..[12]

Fig 1 The excitation-emission matrix (EEM) of a fluorophore is generated by **(a)** acquisition of fluorescence emission
spectra at various excitation wavelengths to produce the **(b)** three-dimensional EEM data set. The **(c)** EEM can be
used to obtain conventional **(d)** excitation and emission spectra by isolating data along a single wavelength on the
excitation or emission axis, respectively.

Excitation–emission matrices (EEMs) are three-dimensional datasets that map fluorescence intensity as a
function of excitation and emission wavelength. They are typically acquired by recording emission spectra
over a series of discrete excitation wavelengths (**Fig 1a,b**). Conceptually, an EEM can be viewed either as
a stack of emission spectra at different excitation wavelengths or, equivalently, as a set of excitation spectra

at fixed emission wavelengths (**Fig 1c,d**). This broad mapping of the excitation-emission properties

provides more comprehensive information than conventional excitation-emission graphs collected at a

single probing wavelength, enabling assessment of excitation-dependent phenomena such as REES. For

fluorophores exhibiting excitation-dependent spectral shifts, EEMs allow derivation of emission spectra

specific to the excitation characteristics of a given sensing system. A significant limitation of EEMs is the

long acquisition times associated with obtaining fluorescence spectra across various excitation

wavelengths. However, recent advances in CCD-based fluorescence spectrometers have enabled the rapid

acquisition of these data sets. These developments provide a promising pathway for utilizing EEMs as a

preferred alternative to individual spectra acquisitions, given their ability to characterize broader aspects of

fluorophore behavior.

Furthermore, because FGS system performance can affect clinical decision-making,[5,6] there is a compelling

need for imaging standards that can help provide 'ground truth' for system characterization.[7,57] In this

context, understanding how the excitation and emission of fluorescence imaging targets can mimic *in vivo*

fluorescence is essential to provide relevant one-to-one equivalence to clinical fluorescence imaging

applications.

Here, we report excitation–emission matrices of ICG in three microenvironments: dimethyl sulfoxide

(DMSO), bovine serum albumin (BSA) solutions, and 3D-printed resin. These measurements establish

comprehensive EEM characterization of ICG that reveal red-edge excitation shifts (REES) and departures

from Kasha's rule for ICG in serum albumin and 3D-printed resin, representing, to our knowledge, the first

report of this phenomenon for ICG and for any FGS fluorophore. The EEM datasets are provided as

supplementary files to support reproducibility, facilitate cross-system benchmarking, and serve as a

reference for optical system development. Collectively, the results highlight new considerations for

generating excitation-specific spectra, guiding FGS system design and comparison, and informing phantom

development for clinically relevant fluorescence imaging.

2 Methods

Preparation of the DMSO, BSA, and 3D-printed samples are described in Sections 2.1–2.3. Procedures for

the fluorescence EEM acquisition, absorbance measurements, and data processing are provided in Sections

2.4–2.6. A complete list of the tested samples is provided in **Table S1** of the Supplementary Material. The

fluorescent samples were prepared using IR-125 laser dye (Exciton Inc., 09030), which is the laser dye

marketing name of ICG (sharing the same Chemical Abstracts Service number, 3599-32-4), with identical

chemical, quantum yield, and fluorescence spectral characteristics.[58] IR-125 dye was utilized for this study,

rather than clinical ICG dye, due to the availability of purity specifications from the respective

manufacturers. Throughout the remainder of this study, the terms IR-125 and ICG are used synonymously.

2.1 Preparation of DMSO solution samples

EEM and absorbance measurements for the DMSO solutions were performed on standard 4.5 mL cuvettes (12×12×45 mm, 10 mm pathlength). A 1000 µM ICG stock solution was prepared in DMSO (Sigma-Aldrich, 472301) to pre-suspend the fluorophore and minimize error during spectral comparisons.

For sample preparation, the 1000 µM stock was diluted with DMSO to yield 100 mL of a 1 µM working solution. A total of 3.5 mL of this 1 µM solution was transferred into a cuvette for data collection, with a matched control cuvette containing 3.5 mL of DMSO (0 µM ICG).

To study concentration-dependent EEM effects, an additional dilution of 100 µM was prepared from the 1000 µM DMSO stock. This 100 µM ICG stock was used to create, through serial dilution, 10 mL samples at concentrations of 10, 3, 1, 0.3, 0.1, and 0.03 µM of ICG in DMSO. Volumes of 3.5 mL of each of these solutions were deposited into cuvettes for data collection with an additional control cuvette of 3.5 mL of DMSO (0 µM ICG).

2.2 Preparation of BSA solution samples

EEM and absorbance measurements for the BSA solutions were performed on standard 4.5 mL cuvettes (12×12×45 mm, 10 mm pathlength). The 1 µM ICG in BSA solution (44 mg/mL) cuvette sample was prepared using the 1000 µM ICG in DMSO stock (Section 2.1), 150 mg/mL BSA stock, and phosphate-buffered saline (PBS). 10× concentrated PBS (Sigma-Aldrich, P7059) was diluted tenfold with distilled water to prepare 1× PBS. Lyophilized BSA powder (Sigma-Aldrich, A2153) was dissolved in the 1x PBS to the 150 mg/mL BSA stock. From these stocks, 100 mL of 1 µM ICG in BSA solution (44 mg/mL BSA) was prepared; 3.5 mL was transferred to a cuvette for data collection, with a matched control cuvette containing 3.5 mL of BSA solution (44 mg/mL, 0 µM ICG). The ICG in BSA solution was incubated at room temperature and protected from light for an hour prior to measurement. It should be noted that the 1000 µM ICG in DMSO stock solution (Section 2.1) was used in this preparation to mitigate the aggregation of dye in PBS solution, which was experimentally observed at these high concentrations. The 44 mg/mL BSA concentration was used as a representative concentration of albumin in human plasma.[59,60]

To study the effect of serum albumin concentration on spectral properties, 1 µM ICG samples were prepared at BSA concentrations of 5, 10, 25, 50, and 100 mg/mL. First, the 1000 µM ICG in DMSO stock (Section 2.1) was diluted with distilled water to prepare a 9 µM ICG aqueous stock. Separately, BSA was diluted with distilled water to generate two sets of 3.5 mL solutions at each target concentration (5-100 mg/mL): one set served as controls (0 µM ICG), and the other set received 389 µL of the 9 µM ICG stock to yield 3.5 mL cuvette samples at 1 µM ICG. Samples containing ICG were incubated at room temperature, protected from light, for 1 h prior to measurement.

2.3 Preparation of 3D-printed samples

The 1 µM ICG in 3D-printed (3DP) resin and the control (0 µM) samples were prepared using a proprietary clear photocurable resin (MML-REPC-001, QUEL Imaging) and the 1000 µM ICG in DMSO stock solution (Section 2.1). The 3DP samples were prepared following a previously published method.[22] In brief, 100 µL of the ICG stock was mixed into 100 mL of the clear resin and printed using layer-by-layer stereolithography printing (405 nm curing) to produce a fluorescent 3DP cuvette ($12\times12\times40\,mm^3$) to match the dimensions of the standard cuvette samples; a control cuvette (0 µM ICG) was also printed using the same method. After printing, the cuvettes were cleaned with isopropyl alcohol and post-cured utilizing a high-radiance 385 nm light (Solarez, 88903). To minimize scattering of light, the 3DP cuvettes were progressively wet-sanded with distilled water and 1500, 2000, and 3000 grit silicon carbide sandpaper, followed by a two-step liquid polisher (Novus 7100). Sanding and polishing resulted in an optically clear surface, enabling data collection comparable to liquid samples prepared in a standard cuvette.

2.4 Fluorescence excitation-emission matrix acquisition

Fluorescence EEMs and absorbance spectra were collected using a dual fluorescence and absorbance spectrometer (Duetta, HORIBA Scientific). This spectrometer uses a xenon arc lamp with a monochromator, enabling excitation and absorbance sweeps over the 250–1000 nm range at 1 nm steps. It is equipped with a linear CCD sensor for fluorescence emission capture (250–1050 nm) and a silicon photodiode for absorbance measurements (250 – 1000 nm), utilizing right-angle (90°) excitation-emission geometry. For EEM acquisition, samples were excited from 650 to 900 nm in 1 nm increments, and the resulting fluorescence emission was collected over 600–1000 nm with a spectral resolution of ~0.5 nm (1 pixel). All spectra were collected using a 3 nm excitation and emission bandpass slit size and three measurement accumulations. The reported maximum fluorescence emission values were assumed to have an uncertainty of ±1 nm, consistent with the manufacturer's specified wavelength accuracy. Although the CCD provided a sampling resolution of ~0.5 nm per pixel, the absolute calibration accuracy was ±1 nm and therefore taken as the limiting factor. Excitation values were likewise assumed to have ±1 nm uncertainty, based on acquisition step size and manufacturer specifications. The uncertainty of the reported Stokes shifts was assumed to be ±1.4 nm, obtained by adding the excitation and emission uncertainties in quadrature. Integration times of 1.0–2.0 s were used, with identical integration times maintained for comparative measurements to ensure consistent cross-sample fluorescence emission comparisons. For the varying concentration measurements of DMSO solutions (Section 2.1), the 3 µM and 10 µM samples were recorded with half the integration time to avoid detector saturation; their measured intensity counts were subsequently doubled during data processing to account for integration time differences.

The reported EEMs are calculated by subtracting the acquired data of the corresponding control (0 μM
ICG) sample from the fluorescent sample. The emission spectra at a given excitation were obtained from
plotting the intensity values along the emission axis of the EEM (**Fig 1c,d**). The excitation spectra at a
"monitored" fluorescence wavelength were derived from plotting the intensity values along the excitation
axis of the EEM (**Fig 1c,d**). The integrated fluorescence emission intensity at a given excitation wavelength,
referred to as areas under the curve (AUCs) for the remainder of the paper, were calculated by trapezoidal
numerical integration (implemented using the *trapz* function from the NumPy library) of extracted emission
spectra (650–1000 nm), with emission centroids defined as the equal-area wavelength corresponding to the
integrated distribution. Emission peak maxima were determined as the highest intensity values of the
processed spectra (see Section 2.6 for details on data processing).

2.5 Absorbance spectra acquisition

Absorbance spectra were collected over the 600-1000 nm range at 1 nm step increments utilizing the
spectrometer silicon photodiode detector (see Section 2.4 for instrument details). For all samples, an
integration time of 0.1 s and a band pass slit size of 3 nm were used with corresponding blanks of DMSO,
BSA, and 3DP resin. The reported max absorbance values are assumed to have a ± 1 nm uncertainty, given
the corresponding acquisition step size parameters and manufacturers wavelength accuracy specification.
Absorbance data is reported with units of optical density (OD), where the measured transmission = 10^{-OD}.
The manufacturer provides an absorbance accuracy specification of ± 0.02 OD.

2.6 Data processing

The EEM and absorbance spectra were processed using robust local regression smoothing with a span of
40 nm. The particular method utilized, robust locally estimated scatterplot smoothing (RLOESS), uses
robust locally weighted linear least squares regression with a 2nd degree polynomial model.[61,62] This robust
smoothing allows for the elimination of outlier measurements and generally provided better peak
estimations than traditional smoothing techniques (i.e. Savitzky-Golay filtering) when tested against
Gaussian and skewed Gaussian fits to the spectral data. Furthermore, this robust smoothing provided the
ability to eliminate scattering peaks introduced by the BSA and 3D printed resin. An example of this
scattering artifact elimination by the robust smoothing is shown in **Fig 2**. RLOESS can be implemented
through the use the *smooth* function in MATLAB or, equivalently, in Python with a modified
implementation of the Pypi.org *loess* project,[63,64] which provides equivalent robust weights to the native
MATLAB implementation.

Fig 2 EEMs for samples with inherent scattering (3DP resin and albumin solutions) exhibit a scattering peak along the excitation-emission line **(a)** which can be corrected through the use of the RLOESS smoothing algorithm to result in the post-processed EEMs **(b)**.

3   Results

3.1 ICG in DMSO

The acquired EEM for 1 µM ICG in DMSO and the associated spectra are shown in **Fig 3**. The EEM (**Fig 3a**) maxima for excitation and emission were measured as 792 nm and 826.5 nm, respectively. The corresponding excitation and emission spectra at these maxima are plotted in **Fig 3b**, showing a measured Stokes shift of 34.5 nm**.**

To assess potential spectral shifts in the excitation, spectra corresponding to monitored emission wavelengths between 800 and 840 nm (10 nm steps) were extracted from the EEM data (**Fig 3c**). The identical spectral shapes of the excitation spectra indicate there are no significant shifts in the fluorescence spectral characteristics for varying monitored emission wavelengths.

To evaluate excitation-dependent, spectra from excitation wavelengths in the 770–810 nm range (10 nm steps) were extracted from the EEM data (**Fig 3d**). The identical spectral shapes of the fluorescence emission indicate there are no significant shifts in the fluorescence spectral characteristics for varying excitation wavelengths. The measured emissions maxima, relative peak intensity, centroid, and relative integrated fluorescence AUC for the various excitations are provided in **Table 1**. No excitation-dependent shifts were observed in either the emission peak or centroid, confirming that ICG in DMSO follows classical Kasha–Vavilov behavior.

Fig. 3 EEM and associated spectra for 1 µM ICG in DMSO: **(a)** Top-down plot of the acquired EEM. **(b)** Excitation and emission spectra extracted from the EEM maxima. **(c)** Normalized excitation spectra at varying monitoring emission wavelengths in the 800–840 nm range at 10 nm steps and **(d)** Normalized emission spectra at varying excitation wavelengths in the 770–810 nm range at 10 nm steps.

Table 1: Emission maxima, relative peak intensities, emission centroids, and relative integrated emission AUC extracted from the EEM of 1 µM ICG in DMSO at excitation wavelengths of 770-810 nm (10 nm steps).

Excitation (nm)	Emission Peak	Peak Intensity	Emission Centroid	AUC
770 nm	826.5 nm	0.73	836.5 nm	0.73
780 nm	826.5 nm	0.91	836.5 nm	0.91
790 nm	826.5 nm	1.00	836.5 nm	1.00
800 nm	826.5 nm	0.95	836.5 nm	0.95
810 nm	827.0 nm	0.74	837.0 nm	0.75

The acquired EEMs of ICG in DMSO at varying concentrations of 0.03, 0.1, 0.3, 1.0, 3.0, and 10 µM are provided in **Figure S1** of the Supplementary Material. These measurements showed fluorescence quenching at the 10 µM concentration (**Fig 4a**), concentration-dependent red shifts (CDRS) (**Fig 4b**), and disparities between absorbance and emission spectra due to inner filter effects (IFE) (**Fig 4c,d**). The log-

log plot of maximum fluorescence intensity vs. concentration (**Fig 4a**) shows a constant increase in fluorescence emission vs. concentration for the 0.03–3 µM range with a drop in intensity for the 10 µM concentration. This drop in fluorescence intensity at the highest concentration is most likely attributed to both primary and secondary inner filter effects (IFE), which correspond to quenching caused by attenuation of the excitation beam and re-absorption of emitted fluorescence, respectively.[65]

To simplify discussion of concentration dependent fluorescence shifts, normalized fluorescence emission spectra at 785 nm excitation were extracted from the EEMs (**Fig 4b**). The corresponding measured maximum emission wavelengths and normalized intensities for these plots were: (0.03 µM, 822.0 nm, 0.020), (0.1 µM, 823.0 nm, 0.066), (0.3 µM, 824.0 nm, 0.19), (1 µM, 826.0 nm, 0.52), (3 µM, 830.5 nm, 1.0), and (10 µM, 839.5 nm, 0.89). This red-shift in fluorescence emission maxima for increasing concentrations (termed CDRS), primarily results from the re-absorption of emitted fluorescence.[65]

Fig. 4: Concentration-dependent spectral effects for ICG in DMSO. **(a)** Plot of maximum fluorescence intensity vs. concentration showing a consistent increase for the 0.03–3 µM range with a drop-off in intensity for the 10 µM concentration. **(b)** Normalized fluorescence emission spectra at 785 nm excitation showing concentration-dependent red shifts. **(c)** Absorbance spectra show consistent spectral features over the entire concentration while the **(d)** excitation spectra show broadening and changes due to fluorescence re-absorption for the 3 µM and 10 µM concentrations.

The measured absorbance data is plotted in **Fig 4c,** showing equivalent spectra from the full 0.03–10 μM

concentration range. Data from the 0.03 μM sample was excluded from **Fig 4c** due to the low signal-to-

noise ratio of its absorbance acquisition. **Table S2** in the Supplementary Material contains summarized OD

absorbance measurements for the varying concentrations, showing no significant variation in calculated

molar extinction coefficients (**Table S3** in the Supplementary Material) for the 0.1–10 μM range. In contrast

to absorbance, the excitation spectra (**Fig 4d**) at varying concentrations, generated from EEMs at the **Fig**

4b emission peaks, shows broadening and quenching for the 3 μM and 10 μM concentrations. This

discrepancy between the absorbance and excitation spectra is caused by secondary IFE effects from the re-

absorption of fluorescence emission at these high concentrations.[65]

3.2 ICG in BSA Solution

The acquired EEM for 1 μM ICG in BSA solution (44 mg/mL) and associated spectra are shown in **Fig 5**.

Compared to the ICG in DMSO EEM (**Fig 3a**), the ICG in BSA solution EEM (**Fig 5a**) showed a significant

'rotation' of the central spectra feature, indicating an excitation-dependent REES and, consequently, a

departure from Kasha's rule, with substantial shifts in the emission spectral characteristics across excitation

wavelengths. The EEM maxima for excitation and emission were measured as 794.0 nm and 813.5 nm,

respectively. The corresponding excitation and emission spectra at these maxima are plotted in **Fig 5b**,

showing a measured Stokes shift of 19.5 nm.

To assess spectral shifts in excitation, spectra corresponding to monitored emission wavelengths between

800 and 840 nm (10 nm steps) were extracted from the EEM data (**Fig 5c**). The resulting spectra showed

increasing shifts in excitation maxima, with measured peaks at 788, 793, 798, 801 and 801 nm for monitored

emission wavelengths of 800, 810, 820, 830, and 840 nm, respectively.

To quantify spectral shifts in the fluorescence emission and intensity, spectra from excitation wavelengths

in the 760–820 nm range (10 nm steps) were extracted from the EEM data (**Fig 5d**). The measured

emissions maxima, relative peak intensities, centroids, and relative AUC values for the various excitations

are summarized in **Table 2**. The resulting fluorescence emission spectra showed excitation-dependent

changes in the peak wavelength and centroid, with only minor changes in photon distribution (spectral

broadening) as indicated by the close agreement between peak intensity and AUC ratios. Over the 770–810

nm excitation range, the emission peak and centroid exhibited average red-shifts of 0.35 and 0.26 nm per

nm of excitation, respectively.

Fig. 5 EEM and associated spectra for 1 µM ICG in BSA solution (44 mg/mL). **(a)** Top-down plot of the acquired EEM showing a 'rotation' of the central spectral feature indicating excitation-dependent spectral shifts. **(b)** Excitation and emission spectra extracted from the EEM maxima. **(c)** Normalized excitation spectra at varying monitoring emission wavelengths in the 800–840 nm range at 10 nm steps and **(d)** Normalized emission spectra at varying excitation wavelengths in the 770–810 nm range at 10 nm steps.

Table 2: Emission maxima, relative peak intensities, emission centroids, and relative integrated emission AUC extracted from the EEM of 1 µM ICG in BSA solution (44 mg/mL) at excitation wavelengths of 770–810 nm (10 nm steps).

Excitation (nm)	Emission Peak	Peak Intensity	Emission Centroid	AUC
770 nm	806.5	0.62	819.5 nm	0.66
780 nm	808.0	0.84	820.0 nm	0.88
790 nm	811.0	0.99	822.5 nm	1
800 nm	815.5	1.00	826.0 nm	0.96
810 nm	820.5	0.82	829.5 nm	0.76

The acquired ICG EEMs at different concentrations of BSA in the 5–100 mg/mL range are provided in

Figure S2 of the Supplementary Material. The EEM measurements showed no significant changes in

spectral characteristics for varying BSA mg/mL concentrations within the tested range, which covers the

full range of biologically relevant concentrations.[59,60] To simplify discussion of BSA concentration

dependent fluorescence shifts, normalized fluorescence emission spectra at 785 nm excitation were

extracted from the EEMs (**Fig 6**). The excitation plots (**Fig 6a**), obtained by monitoring fluorescence at the

emission maximum and normalized by the set maxima, show no significant spectral changes, with all

excitation peak maxima at 803 nm. Similarly, the fluorescence emission plots (**Fig 6b**), normalized by the

set maxima, show no significant changes in the photon distributions of the emission. The measured

maximum emissions and normalized intensities for the various concentrations of BSA were: (5 mg/mL,

816.0 nm, 0.96), (10 mg/mL, 815.5 nm, 0.96), (25 mg/mL, 815.5 nm, 0.97), (50 mg/mL, 815.0 nm, 0.94),

and (100 mg/mL, 815.5 nm, 1.0).

Fig. 6 Fluorescence measurements of ICG in 5–100 mg/mL BSA solutions at 785 nm excitation: **(a)** relative excitation

spectra obtained at the monitored peak emission wavelength, and **(b)** relative emission spectra, both indicating no

significant changes in spectral characteristics across concentrations.

3.3 ICG in 3DP Resin

The acquired EEM for 1 µM ICG in 3DP resin and associated spectra are shown in **Fig 7**. Compared to the

ICG in DMSO EEM (**Fig 3a**), the ICG in 3DP resin EEM (**Fig 7a**) showed a significant 'rotation' of the

central spectra feature, indicating an excitation-dependent REES and, consequently, a departure from

Kasha's rule, with substantial shifts in the emission spectral characteristics across excitation wavelengths.[12]

The EEM maxima for excitation and emission were measured as 809 nm and 823.5 nm, respectively. The

corresponding excitation and emission spectra at these maxima are plotted in **Fig 7b**, showing a measured

Stokes shift of 14.5 nm**.**

To assess spectral shifts in excitation, spectra corresponding to monitored emission wavelengths between
800 and 840 nm (10 nm steps) were extracted from the EEM data (**Fig 5c**). The resulting spectra showed
increasing shifts in excitation maxima, with measured peaks at 793, 799, 806, 811 and 815 nm for monitored
emission wavelengths of 800, 810, 820, 830, and 840 nm, respectively.

Fig. 7 EEM and associated spectra for 1 µM ICG in 3DP resin. **(a)** Top-down plot of the acquired EEM showing a
'rotation' of the central spectral feature indicating excitation-dependent spectral shifts. **(b)** Excitation and emission
spectra extracted from the EEM maxima. **(c)** Normalized excitation spectra at varying monitoring emission
wavelengths in the 800–840 nm range at 10 nm steps and **(d)** Normalized emission spectra at varying excitation
wavelengths in the 770–810 nm range at 10 nm steps.

Table 3: Emission maxima, relative peak intensities, emission centroids, and relative integrated emission AUC
extracted from the EEM of 1 µM ICG in 3DP Resin at excitation wavelengths of 770-810 nm (10 nm steps).

Excitation (nm)	Emission Peak	Peak Intensity	Emission Centroid	AUC
770 nm	809.0 nm	0.44	824.5 nm	0.62
780 nm	810.5 nm	0.61	825.0 nm	0.76
790 nm	815.0 nm	0.79	827.5 nm	0.9
800 nm	819.0 nm	0.96	831.0 nm	1
810 nm	824.0 nm	1.00	835.5 nm	0.99

To quantify spectral shifts in the fluorescence emission, spectra from excitation wavelengths in the 760–
820 nm range (10 nm steps) were extracted from the EEM data (**Fig 7d**). The measured emissions maxima,
relative peak intensities, centroids, and relative AUC values for the various excitations are summarized in
Table 3. The resulting fluorescence emission spectra showed excitation-dependent changes in the peak
wavelength and centroid, with noticeable changes in photon distribution (spectral broadening), as reflected
by differences between peak intensity and AUC ratios. Over the 770–810 nm excitation range, the emission
peak and centroid exhibited average red-shifts of 0.39 and 0.26 nm per nm of excitation, respectively.

3.4 ICG Spectral Comparison

The absorbance spectra, excitation spectra for the integrated emission AUC, and emission spectra at 760,
785 nm and 805 nm excitation for 1 μM ICG in DMSO, BSA solution (44 mg/mL), and 3DP resin are
shown in **Fig 8,** with summarized data provided in **Table 4**. Because the BSA solution and 3DP resin
exhibited excitation-dependent emission behavior (**Fig. 5** & **Fig. 7**), excitation-specific spectra provide an
appropriate basis for comparing fluorescence responses across microenvironments in fluorescence sensing
applications. Accordingly, fluorescence emission spectra for 760, 785, and 805 nm excitation are shown in
Fig. 8c–h, representing three of the most common excitation wavelengths used for ICG imaging in FGS
devices.[7]

The absorbance spectra (**Fig 8a**) showed maxima at 792, 795, and 807 nm for DMSO, BSA solution, and
3DP resin, respectively. The corresponding peak ODs differed by less than 5% in transmission, calculated
as 10^{-OD} (**Table 1**). The excitation spectra (**Fig 8b**), calculated from the integrated emission AUC, showed
similar differences in peak positions, with maxima at 791, 792, and 805 nm.

The emission spectra demonstrated notable differences in spectral overlap arising from the excitation-
dependent behavior of the BSA solution and 3DP resin samples (**Fig. 8d,f,h**). At 760 nm excitation (**Fig.
8c,d**), the 3DP resin spectra was broad, overlapping with both the DMSO and BSA solution, while DMSO
and BSA spectra showed limited overlap (**Fig. 8d**). At 785 nm excitation (**Fig. 8e,f**), the spectra of the
BSA solution and 3DP showed substantial overlap (**Fig.8f**) with nearly identical AUC intensities (**Fig 8e**,
Table 4). At 805 nm excitation (**Fig. 8g,h**), the emission spectra of all three samples showed substantial
overlap (**Fig. 8h**). Furthermore, the excitation-dependent peak maxima, centroids, and integrated emission
AUC, and photon distributions highlight the need to consider the excitation wavelength and emission
collection of the fluorescence sensing device to provide relevant comparisons within varying fluorophore
microenvironments and system design parameters. The observed excitation-dependent emissions, leading
to non-linear shifts in the emission peaks and centroids, are further examined in Section 3.5.

Table 4: Summarized data for the comparison of the spectral behavior of ICG in DMSO, BSA solution and 3DP
resin microenvironments. The integrated emission AUC is normalized to the counts of the DMSO solution emission
maxima at the 785 nm excitation.

	Absorbance		Excitation	Emission @ 760 nm excitation			Emission @ 785 nm excitation			Emission @ 805 nm excitation		
	Peak (nm)	OD	Peak (nm)	Peak (nm)	Centroid (nm)	AUC (Norm)	Peak (nm)	Centroid (nm)	AUC (Norm)	Peak (nm)	Centroid (nm)	AUC (Norm)
DMSO	792	0.167	791	826.5	836.5	0.60	826.5	836.5	1.00	827.0	837.0	0.89
Albumin	795	0.142	792	808.0	821.0	0.24	810.0	821.0	0.47	819.5	828.0	0.43
3DP Resin	807	0.159	805	819.0	826.5	0.33	813.0	826.0	0.54	821.0	833.0	0.66

Fig. 8 Spectral comparisons of 1 μM ICG in DMSO, BSA solution (44 mg/mL), and 3DP Resin: **(a)** Absorbance

spectra, (b) excitation spectra calculated from the EEM emission AUC, **(c,d)** fluorescence emission spectra at 760 nm

excitation, **(e,f)** fluorescence emission spectra at 785 nm excitation, and **(g,h)** fluorescence emission spectra at 805

nm excitation.

3.5 Excitation-Dependency and Red-edge Shift Comparisons

To further explore excitation-dependent effects on the emission spectra, plots of emission peak vs.
excitation and emission centroid vs. excitation were generated from the respective EEMs for 1 µM ICG in
DMSO, BSA solution (44 mg/mL), and 3DP resin (**Fig. 9**). It is worth noting that the centroid plots showed
reduced noise compared to the peak plots due to the variance-reducing effect of AUC integration. For ICG
in DMSO (**Fig. 9a,d**), neither the emission peak nor the centroid wavelength exhibited significant variation
with excitation wavelength, consistent with classical Kasha rule behavior and excitation-independent
emission. In contrast, ICG in BSA solution (**Fig. 9b,e**) and in 3DP resin (**Fig. 9c,f**) showed pronounced
shifts in both peak and centroid emission wavelengths as a function of excitation, demonstrating strong
non-linear excitation-dependence and red-edge effects. Both the BSA solution and 3DP resin show a local
maxima at ~740-750 nm range, followed by a pronounced REES trend at excitation wavelengths >770 nm.
Notably, this localized increase extends beyond the traditional REES behavior, providing strong evidence
of anti-Kasha emission dynamics and suggesting that ICG may undergo multiple relaxation pathways
depending on excitation wavelength for the BSA solution and 3DP resin microenvironments.

Fig 9 Emission peak **(a-c)** and centroid **(d-f)** vs. excitation wavelength plot of 1 µM ICG in DMSO, BSA solution,
and 3DP resin: The peak emission wavelength for **(a)** ICG in DMSO showed no significant variation with excitation
wavelength while the **(b)** BSA solution and **(c)** 3DP resin data showed significant, non-linear, variations that include
REES. The emission centroid wavelength for **(d)** ICG in DMSO showed no significant variation with excitation
wavelength while the **(e)** BSA solution and **(f)** 3DP resin data showed significant, non-linear, variations that include
REES.

4 Discussion

Here we reported EEM and absorbance measurements of ICG in DMSO, BSA solutions, and 3DP resin, together with extracted excitation and emission spectra and quantitative summaries of emission peaks, centroids, and integrated emission AUCs. ICG in DMSO exhibited excitation-independent emission consistent with Kasha–Vavilov behavior, whereas the BSA solution and 3DP resin showed significant excitation-dependent emission, including REES and non-linear departures from Kasha's rule. To our knowledge, this is the first report of such excitation-dependent phenomena for ICG and for any FGS fluorophore, highlighting the importance of considering excitation-dependent effects in both comparative spectral analysis and sensing system design. The subsequent subsections provide detailed discussion of each set of results.

4.1 ICG in DMSO

The EEM for 1 μM ICG in DMSO (**Fig 3**) provided 'symmetric' spectra throughout the varying excitation wavelengths with measured emission peaks of 826.5 nm ± 0.5 nm over the 760 – 810 nm excitation range. This EEM confirms the conventional Kasha-rule fluorophore behavior that assumes invariant spectral photon distribution of fluorescence emission with excitation wavelength.

The EEMs and absorbance at varying ICG concentrations in DMSO (**Fig 4**) show the effects of concentration-dependent fluorescence shifts including fluorescence quenching, CDRS, and disparities between the absorbance and excitation spectra due to IFEs. Increases in fluorophore concentration lead to a proportional increase in fluorescence emission intensity within a linear range, followed by a decrease at higher concentrations due to IFEs or fluorophore aggregation; this concentration-quenching is well understood and reported both experimentally and through Monte Carlo photon transport simulations.[65–67] The measured linear range for ICG in DMSO was 0.3 – 3 μM with the 10 μM sample showing significant quenching, emission shifts (CDRS) and distortion of the excitation spectra. The 3 μM sample exhibited minor quenching, CDRS, and excitation spectra broadening. Within the linear range, the measured EEMs (**Fig S1**) demonstrated no significant differences, displaying an anticipated increase in emission intensity proportional to concentration across the entire wavelength matrix. The spectral distribution of the absorbance spectra was consistent along the full concentration range, which indicates that the observed fluorescence shifts are due to IFEs and not fluorophore aggregation at these high concentrations. The photon distribution of the absorbance and excitation spectra were equivalent within the identified linear range. It is worth noting that this measured linearity range is specific to the geometry of the spectral measurement, which utilized an orthogonal excitation-emission collection with a 10 mm pathlength. These results highlight the need to understand the linearity range of a fluorophore to adequately choose concentrations for EEM and fluorescence spectra characterization.

4.2 ICG in BSA solution

In contrast to the ICG in DMSO sample, the 1 µM ICG in BSA solution (**Fig 5**) showed a 'rotation' of the

central spectral feature indicating excitation-dependent emission, REES, and departures from Kasha's rule.

This nonlinear effect is most likely attributed to albumin binding[21,68] causing changes in solvent relaxation

times, where the excitation red shift is observed because relaxation is not complete before fluorescence

emission occurs.[12] Quantitatively, average emission red-shift slopes of 0.35 nm·nm⁻¹ (peak) and 0.26

nm·nm⁻¹ (centroid) were observed over the 770–810 nm excitation range (**Table 2**), with only minor

changes in spectral photon distributions. These results emphasize the importance of EEM fluorophore

measurements to characterize excitation-dependent effects associated with biologically-relevant

microenvironments.

EEM measurements for ICG in varying BSA concentration solutions (**Fig 6, Figure S2**) showed the same

excitation-dependent behavior, with no significant spectral differences within the biologically-relevant

albumin concentrations in the 5–100 mg/mL range.[59,60] Consideration of excitation-dependent emission

shifts for ICG in BSA solutions could help optimize fluorescence sensing designs including FGS imagers

given the relevancy to perfusion and *in vivo* applications. The measured ICG EEM in the BSA solution (**Fig

5**) provides spectral information for albumin concentrations found in whole blood,[60,69] thus serving as a

good estimator of *in vivo* ICG spectra for perfusion applications. Furthermore, the invariability of the EEM

within the wide albumin concentration range indicates that it might be a suitable estimator of interstitial

ICG spectra.[69]

It is worth noting that while higher BSA concentrations introduced greater excitation scattering peaks in

the raw data, these effects were successfully addressed by the robust smoothing approach (see Section 2.6),

yielding equivalent EEMs and emission spectra across the full concentration range. This demonstrates that

the technique can handle varying levels of scattering without negatively affecting the processed results or

introducing artifacts within the tested signal-to-noise ratios and smoothing span.

4.3 ICG in 3DP resin

Similarly to the ICG in BSA solution EEM, the ICG in 3DP resin EEM (**Fig 7**) showed a 'rotation' of the

central spectral feature indicating excitation-dependent emission, REES, and departures from Kasha's rule.

Quantitatively, the average emission red-shift slopes were 0.39 nm·nm⁻¹ (peak) and 0.26 nm·nm⁻¹

(centroid) over 770–810 nm, with noticeable changes to spectral photon distribution (broadened spectra)

evident from differences between peak-intensity and AUC trends (**Table 3**). These nonlinear effects are

most likely attributed to the embedding of the fluorophore within a solid polymer matrix, causing changes

in relaxation times, where the excitation red shift is observed because relaxation is not complete before

fluorescence emission occurs.[12] Given the intended use of these 3DP fluorescent materials as 'ground-truth'

measurements, in the form of reference targets and phantoms,[7,22,23,57] the presence of excitation-dependent

emission underscores the need to consider the excitation wavelength for accurate, application-specific, and

system-specific characterization and comparisons.

4.4 ICG Spectral comparison

The spectral comparison of 1 µM ICG in DMSO, BSA solution, and 3DP resin (**Fig 8**), showed shifts in

spectral emission wavelengths and distributions, including excitation-dependent effects in the BSA and

3DP samples. Given the excitation-dependent spectral behavior, and because fluorescence sensing relies

on emitted light, emission spectra at defined excitation wavelengths provide the most appropriate basis for

comparison. In this context, the BSA solution and 3DP resin samples exhibited substantial spectral overlap

at excitation wavelengths commonly used in FGS devices (760–805 nm, **Fig 8d,f,h**); this suggests that the

ICG in 3DP resin can serve as an adequate surrogate reference material for albumin-bound ICG. However,

meaningful comparison requires accounting not only for excitation conditions but also for the specific

emission collection parameters of the sensing system.

Considering that the fluorophore spectral emission can vary with both microenvironment and excitation

wavelength, the most accurate method for comparing fluorescence emission intensity involves integrating

the excitation-specific emission spectra within the sensing system's detection band (such as long-pass

emission collection, band-pass emission collection, etc.). The acquired EEM dataset facilitates application

and system-specific comparisons, incorporating considerations of both excitation and emission collection

parameters. It is important to note that the provided EEMs (Supplementary Data Files) are directly

comparable in their reported intensities since identical acquisition parameters were used. Although not

explored in our analysis, it is worth noting that 'weighted emission spectra' can be generated from the

provided EEMs for broadband excitation sources.

4.5 Excitation-Dependency and Red-edge Shift Comparisons

The peak and centroid versus excitation plots (**Fig. 9**) showed three distinct behaviors. In DMSO, emission

is effectively excitation-independent, following Kasha's rule, and serves as the baseline for traditional

fluorophore behavior assumptions. In BSA solution and 3DP resin, pronounced red-edge excitation shifts

emerge for excitations ≥ ~770 nm, indicating that varied excitation alongside partial vibronic relaxation

produce excitation-dependent emission. Additionally, a localized maxima near 740–750 nm precedes the

REES trend in both media, pointing to extra microstate selectivity not captured by a simple monotonic shift

and representing a more complex departure from Kasha's rule. The detailed mechanistic explanation for

these complex excitation-dependent effects lies beyond the scope of the present work but represents an

important direction for further study.

4.6 Future work and Limitations

The presented EEM and absorbance measurements provided comprehensive insights into ICG excitation-dependent spectral shifts in varying microenvironments but were limited to room-temperature conditions. It is worth noting that the captured EEMs contain some "banding" along the emission axis (see **Fig. 3a, 5a, 7a**) for excitation wavelengths in the ~820–860 nm range. These artifacts result from limitations in the spectrofluorometer's correction of xenon lamp spectral peaks during intensity normalization, as confirmed through communication with the manufacturer. Because the robust smoothing applied to the data was performed independently on each emission spectrum rather than across the excitation axis (the y-axis in the top-down EEM plots), these banding artifacts were not removed. However, the reported peak emissions, centroids, and integrated AUCs, as well as the extracted excitation and emission spectra, were minimally affected, since the relevant excitation range for ICG fluorescence sensing applications lies within the 650–820 nm range.

Further insights could be gained by including whole blood in the suite of tested solvents. Although the high absorption and scattering in whole blood may pose measurement challenges, understanding excitation-dependence in this context would improve the *in vivo* spectral estimations. Moreover, conducting *in vivo* fluorescence spectral measurements, which would require specialized equipment, could further characterize the effects of albumin binding on *in-vivo* ICG EEM shifts. Characterizing how temperature influences EEMs and excitation-dependent behavior would provide valuable insights. Additionally, IFE corrections[70] and spectral unmixing of EEMs could further help advance fluorophore characterization, including understanding of non-linear and aggregation effects. Future studies that measure absolute quantum yields at varying excitation wavelengths in BSA solutions and 3DP resin could provide further insight into the extent of deviation from Kasha–Vavilov behavior.

As FGS-targeted fluorophores continue to develop, measuring EEM spectra for bound fluorophores that mimic the *in vivo* environment will be crucial for understanding their behavior and the extent of excitation-dependence and deviations from Kasha's rule. These assessments are further complicated by the diverse chemical environments of targeted binding sites. If solvent-related excitation effects are found to be minimal, this could indicate 'robust' spectral properties, with little to no shift observed despite changes in microenvironment. Conversely, pronounced excitation-dependent spectral changes would be important to identify prior to clinical application, as they could inform imaging system design or motivate modification of the fluorophore structure.

5 Conclusion

This study presents comprehensive EEM characterization of ICG in DMSO, BSA solutions, and 3DP resin microenvironments, revealing significant excitation-dependent emission, including REES and non-linear departures from Kasha's rule, in the BSA solution and 3DP resin; in contrast, DMSO exhibited traditional excitation-independent (Kasha–Vavilov) behavior. These results provide, to our knowledge, the first documentation of REES and broader deviation from Kasha's rule for ICG and any FGS fluorophore. The findings highlight the need to account for excitation-dependent emission when comparing spectra across systems and microenvironments. The observed excitation-dependent shifts also support the use of excitation-specific, EEM-derived spectra for system design, inter-system comparisons, and phantom development; notably, the substantial emission overlap between BSA solution and 3DP resin spectra at commonly used excitation wavelengths (~760–805 nm) suggests that ICG in 3DP resin can serve as a stable surrogate reference for albumin-bound ICG when system excitation and emission collection parameters are considered.[7,22,57] The EEM datasets provided here offer a practical reference for fluorophore characterization and benchmarking that incorporate excitation-dependent effects. Future work extending these measurements to additional physiological conditions (i.e., temperature variation, whole blood, and *in vivo* contexts) and absolute quantum-yield assessments at varying excitations will further clarify excitation-dependent behavior and its implications for fluorophore chemistry, spectral comparisons, and fluorescence-based imaging system design.

Disclosures

AJR and EPML are co-founders of QUEL Imaging, which is a medical imaging phantom company. SAL and KSS declare no conflicts of interest.

Acknowledgments

This work was partially funded by the NIBIB R44 grant EB029804-02 and the Dartmouth Innovation Program Fellowship.

The authors also acknowledge the use of the ChatGPT-5 language model (OpenAI) and the Microsoft Word Editor tools for editorial editing, grammar correction, and text refinement.

Data, Materials, and Code Availability

Data and code are available upon reasonable request.

References

1. "Chemical Sensing via Fluorescence," in Molecular Fluorescence, pp. 409–478, John Wiley & Sons, Ltd (2012) [doi:10.1002/9783527650002.ch14].

2. "Autofluorescence and Fluorescence Labeling in Biology and Medicine," in Molecular Fluorescence, pp. 479–505, John Wiley & Sons, Ltd (2012) [doi:10.1002/9783527650002.ch15].

3. Z. Yang et al., "Macro-/micro-environment-sensitive chemosensing and biological imaging," Chem Soc Rev **43**(13), 4563–4601 (2014) [doi:10.1039/C4CS00051J].

4. N. O. Mchedlov-Petrossyan, N. A. Vodolazkaya, and A. O. Doroshenko, "Ionic Equilibria of Fluorophores in Organized Solutions: The Influence of Micellar Microenvironment on Protolytic and Photophysical Properties of Rhodamine B," 14.

5. M. Koch, P. Symvoulidis, and V. Ntziachristos, "Tackling standardization in fluorescence molecular imaging," Nat. Photonics **12**(9), 505 (2018) [doi:10.1038/s41566-018-0221-5].

6. B. W. Pogue et al., "Fluorescence-guided surgery and intervention — An AAPM emerging technology blue paper," Med. Phys. **45**(6), 2681–2688 (2018) [doi:10.1002/mp.12909].

7. M. I. Ochoa et al., "Assessment of open-field fluorescence guided surgery systems: implementing a standardized method for characterization and comparison," J. Biomed. Opt. **28**(9), 096007, SPIE (2023) [doi:10.1117/1.JBO.28.9.096007].

8. A. V. DSouza et al., "Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging," J. Biomed. Opt. **21**(8) (2016) [doi:10.1117/1.JBO.21.8.080901].

9. J. R. Lakowicz, Ed., "Solvent and Environmental Effects," in Principles of Fluorescence Spectroscopy, pp. 205–235, Springer US, Boston, MA (2006) [doi:10.1007/978-0-387-46312-4_6].

10. "Environmental Effects on Fluorescence Emission," in Molecular Fluorescence, pp. 109–140, John Wiley & Sons, Ltd (2012) [doi:10.1002/9783527650002.ch5].

11. A. Chattopadhyay and S. Mukherjee, "Fluorophore environments in membrane-bound probes: A red edge excitation shift study," Biochemistry **32**(14), 3804–3811 (1993) [doi:10.1021/bi00065a037].

12. J. R. Lakowicz, Ed., "Dynamics of Solvent and Spectral Relaxation," in Principles of Fluorescence
Spectroscopy, pp. 237–276, Springer US, Boston, MA (2006) [doi:10.1007/978-0-387-46312-4_7].

13. D. C. Khara and A. Samanta, "Solvation dynamics and red-edge effect of two electrically charged solutes in an
imidazolium ionic liquid," INDIAN J CHEM (2010).

14. M. Kasha, "Characterization of electronic transitions in complex molecules," Discuss. Faraday Soc. **9**, 14
(1950) [doi:10.1039/df9500900014].

15. S. I. Vavilov, "*The dependence of the intensity of the fluorescence of dyes upon the wave-length of the exciting*
light," Lond. Edinb. Dublin Philos. Mag. J. Sci. **43**(254), 307–320 (1922) [doi:10.1080/14786442208565217].

16. M. Maafi, "Kasha's Rule and Photochemistry," in Photokinetics: A New Perspective, M. Maafi, Ed., pp. 73–
117, Springer Nature Switzerland, Cham (2025) [doi:10.1007/978-3-031-98985-8_4].

17. A. K. Prasad and M. Jain, "Breakdown of Kasha's Rule in a Ubiquitous, Naturally Occurring, Wide Bandgap
Aluminosilicate (Feldspar)," Sci. Rep. **8**(1), 810, Nature Publishing Group (2018) [doi:10.1038/s41598-017-
17466-z].

18. H.-W. Tseng et al., "Excited-state intramolecular proton-transfer reaction demonstrating anti-Kasha behavior,"
Chem. Sci. **7**(1), 655–665 (2016) [doi:10.1039/C5SC01945A].

19. M. Uttamlal and A. Sheila Holmes-Smith, "The excitation wavelength dependent fluorescence of porphyrins,"
Chem. Phys. Lett. **454**(4–6), 223–228 (2008) [doi:10.1016/j.cplett.2008.02.012].

20. K. Veys and D. Escudero, "Anti-Kasha Fluorescence in Molecular Entities: Central Role of Electron–
Vibrational Coupling," Acc. Chem. Res. **55**(18), 2698–2707 (2022) [doi:10.1021/acs.accounts.2c00453].

21. S. Yoneya et al., "Binding properties of indocyanine green in human blood.," Invest. Ophthalmol. Vis. Sci.
39(7), 1286–1290 (1998).

22. A. J. Ruiz et al., "3D printing fluorescent material with tunable optical properties," Sci. Rep. **11**(1), 17135
(2021) [doi:10.1038/s41598-021-96496-0].

23. A. J. Ruiz et al., "Indocyanine green matching phantom for fluorescence-guided surgery imaging system
characterization and performance assessment," J. Biomed. Opt. **25**(05), 1 (2020)
[doi:10.1117/1.JBO.25.5.056003].

24. J. A. Zelken and A. P. Tufaro, "Current Trends and Emerging Future of Indocyanine Green Usage in Surgery
and Oncology: An Update," Ann. Surg. Oncol. **22**(S3), 1271–1283 (2015) [doi:10.1245/s10434-015-4743-5].

25. J. T. Alander et al., "A Review of Indocyanine Green Fluorescent Imaging in Surgery," International Journal of
Biomedical Imaging, 2012, [doi:10.1155/2012/940585] (accessed 25 November 2019).

26. V. L. Dzurinko, A. S. Gurwood, and J. R. Price, "Intravenous and indocyanine green angiography," Optom. - J.
Am. Optom. Assoc. **75**(12), 743–755 (2004) [doi:10.1016/S1529-1839(04)70234-1].

27. M. Koch and V. Ntziachristos, "Advancing Surgical Vision with Fluorescence Imaging," Annu. Rev. Med.
67(1), 153–164 (2016) [doi:10.1146/annurev-med-051914-022043].

28. M. V. Marshall et al., "Near-Infrared Fluorescence Imaging in Humans with Indocyanine Green: A Review and
Update," Open Surg. Oncol. J. Online **2**(2), 12–25 (2010) [doi:10.2174/1876504101002010012].

29. M. L. Landsman et al., "Light-absorbing properties, stability, and spectral stabilization of indocyanine green,"
J. Appl. Physiol. **40**(4), 575–583 (1976) [doi:10.1152/jappl.1976.40.4.575].

30. B. Yuan, N. Chen, and Q. Zhu, "Emission and absorption properties of indocyanine green in Intralipid
solution," J. Biomed. Opt. **9**(3), 497–503, SPIE (2004) [doi:10.1117/1.1695411].

31. B. Chon et al., "Indocyanine Green (ICG) Fluorescence Is Dependent on Monomer with Planar and Twisted
Structures and Inhibited by H-Aggregation," Int. J. Mol. Sci. **24**(17), 13030, Multidisciplinary Digital
Publishing Institute (2023) [doi:10.3390/ijms241713030].

32. R. Mačianskienė et al., "Spectral characteristics of voltage-sensitive indocyanine green fluorescence in the
heart," Sci. Rep. **7**(1), 7983, Nature Publishing Group (2017) [doi:10.1038/s41598-017-08168-7].

33. A. Yu et al., "Solvatochromism and Solvation Dynamics of Structurally Related Cyanine Dyes," J. Phys.
Chem. A **106**(41), 9407–9419 (2002) [doi:10.1021/jp0205867].

34. Bongsu Jung, V. I. Vullev, and B. Anvari, "Revisiting Indocyanine Green: Effects of Serum and Physiological
Temperature on Absorption and Fluorescence Characteristics," IEEE J. Sel. Top. Quantum Electron. **20**(2),
149–157 (2014) [doi:10.1109/JSTQE.2013.2278674].

35. Y. Li et al., "A human serum albumin-indocyanine green complex offers improved tumor identification in
fluorescence-guided surgery," Transl. Cancer Res. **13**(1), AME Publishing Company (2024) [doi:10.21037/tcr-
23-2338].

36. C. C. L. Cheung et al., "Liposome-Templated Indocyanine Green J- Aggregates for *In Vivo* Near Infrared
Imaging and Stable Photothermal Heating," Nanotheranostics **4**(2), 91–106 (2020) [doi:10.7150/ntno.41737].

37. J. C. Kraft and R. J. Y. Ho, "Interactions of Indocyanine Green and Lipid in Enhancing Near-Infrared
Fluorescence Properties: The Basis for Near-Infrared Imaging *in Vivo*," Biochemistry **53**(8), 1275–1283 (2014)
[doi:10.1021/bi500021j].

38. N. B. Stern, B. Shrestha, and T. Porter, "A Facile Approach to Producing Liposomal J-Aggregates of
Indocyanine Green with Diagnostic and Therapeutic Potential," Adv. Ther. **7**(8), 2400042 (2024)
[doi:10.1002/adtp.202400042].

39. J. Cho et al., "Monitoring Distribution of the Therapeutic Agent Dimethyl Sulfoxide via Solvatochromic Shift
of Albumin-Bound Indocyanine Green," Sensors **23**(18), 7728 (2023) [doi:10.3390/s23187728].

40. R. S. Gamage and B. D. Smith, "Spontaneous Transfer of Indocyanine Green from Liposomes to Albumin Is
Inhibited by the Antioxidant α-Tocopherol," Langmuir **38**(39), 11950–11961 (2022)
[doi:10.1021/acs.langmuir.2c01715].

41. M. Y. Berezin et al., "Near Infrared Dyes as Lifetime Solvatochromic Probes for Micropolarity Measurements
of Biological Systems," Biophys. J. **93**(8), 2892–2899 (2007) [doi:10.1529/biophysj.107.111609].

42. C. Vinegoni et al., "Indocyanine Green Enables Near-Infrared Fluorescence Imaging of Lipid-Rich, Inflamed
Atherosclerotic Plaques," Sci. Transl. Med. **3**(84) (2011) [doi:10.1126/scitranslmed.3001577].

43. R. H. Patel et al., "Multifunctionality of indocyanine green-loaded biodegradable nanoparticles for enhanced
optical imaging and hyperthermia intervention of cancer," J. Biomed. Opt. **17**(4), 046003 (2012)
[doi:10.1117/1.JBO.17.4.046003].

44. E. I. Altınoğlu et al., "Near-Infrared Emitting Fluorophore-Doped Calcium Phosphate Nanoparticles for *In Vivo*
Imaging of Human Breast Cancer," ACS Nano **2**(10), 2075–2084 (2008) [doi:10.1021/nn800448r].

45. Z. Starosolski et al., "Indocyanine green fluorescence in second near-infrared (NIR-II) window," PLOS ONE
12(11), C. L. Evans, Ed., e0187563 (2017) [doi:10.1371/journal.pone.0187563].

46. V. I. Kochubey, "Spectral Characteristics of Indocyanine Green upon Its Interaction with Biological Tissues,"
Opt. Spectrosc. **99**(4), 560 (2005) [doi:10.1134/1.2113369].

47. T. Desmettre, J. M. Devoisselle, and S. Mordon, "Fluorescence Properties and Metabolic Features of
Indocyanine Green (ICG) as Related to Angiography," Surv. Ophthalmol. **45**(1), 15–27 (2000)
[doi:10.1016/S0039-6257(00)00123-5].

48. U. Kanniyappan et al., "Near-infrared fluorescence image quality test methods for standardized performance
evaluation," presented at SPIE BiOS, 21 March 2017, San Francisco, California, United States, 100560J
[doi:10.1117/12.2255867].

49. J. R. Lakowicz and S. Keating-Nakamoto, "Red-edge excitation of fluorescence and dynamic properties of
proteins and membranes," Biochemistry **23**(13), 3013–3021 (1984) [doi:10.1021/bi00308a026].

50. A. P. Demchenko, "The red-edge effects: 30 years of exploration," Luminescence **17**(1), 19–42 (2002)
[doi:10.1002/bio.671].

51. M. L. Kabir, F. Wang, and A. H. A. Clayton, "Red-Edge Excitation Shift Spectroscopy (REES): Application to Hidden Bound States of Ligands in Protein–Ligand Complexes," Int. J. Mol. Sci. **22**(5), 2582 (2021) [doi:10.3390/ijms22052582].

52. A. K. Warrender et al., "Red edge excitation shift spectroscopy is highly sensitive to tryptophan composition," J. R. Soc. Interface **20**(208), 20230337 (2023) [doi:10.1098/rsif.2023.0337].

53. D. A. M. Catici et al., "The red edge excitation shift phenomenon can be used to unmask protein structural ensembles: implications for NEMO–ubiquitin interactions," FEBS J. **283**(12), 2272–2284 (2016) [doi:10.1111/febs.13724].

54. J. R. Lakowicz, "On Spectral Relaxation in Proteins†¶‖," Photochem. Photobiol. **72**(4), 421–437 (2007) [doi:10.1562/0031-8655(2000)0720421OSRIP2.0.CO2].

55. A. Chattopadhyay, "Exploring membrane organization and dynamics by the wavelength-selective fluorescence approach," Chem. Phys. Lipids **122**(1–2), 3–17 (2003) [doi:10.1016/S0009-3084(02)00174-3].

56. R. S. DaCosta, H. Andersson, and B. C. Wilson, "Molecular Fluorescence Excitation-Emission Matrices Relevant to Tissue Spectroscopy¶," Photochem. Photobiol. **78**(4), 384–392 (2007) [doi:10.1562/0031-8655(2003)0780384MFEMRT2.0.CO2].

57. E. P. M. LaRochelle et al., "3D-Printed Tumor Phantoms for Assessment of In Vivo Fluorescence Imaging Analysis Methods," Mol. Imaging Biol. **25**(1), 212–220 (2023) [doi:10.1007/s11307-022-01783-5].

58. S. Reindl et al., "Quantum yield of triplet formation for indocyanine green," J. Photochem. Photobiol. Chem. **105**(1), 65–68 (1997) [doi:10.1016/S1010-6030(96)04584-4].

59. "5 Human Albumin," Transfus. Med. Hemotherapy **36**(6), 399–407 (2009).

60. S. Choi et al., "A rapid, simple measurement of human albumin in whole blood using a fluorescence immunoassay (I)," Clin. Chim. Acta **339**(1–2), 147–156 (2004) [doi:10.1016/j.cccn.2003.10.002].

61. I. Gijbels and I. Prosdocimi, "Loess," WIREs Comput. Stat. **2**(5), 590–599 (2010) [doi:10.1002/wics.104].

62. W. S. Cleveland and S. J. Devlin, "Locally Weighted Regression: An Approach to Regression Analysis by Local Fitting," J. Am. Stat. Assoc. **83**(403), 596–610, Taylor & Francis (1988) [doi:10.1080/01621459.1988.10478639].

63. M. Cappellari, "loess: LOESS: smoothing via robust locally-weighted regression in one or two dimensions," Python.

64. M. Cappellari et al., "The ATLAS3D project - XX. Mass-size and mass-σ distributions of early-type galaxies: bulge fraction drives kinematics, mass-to-light ratio, molecular gas fraction and stellar initial mass function," Mon. Not. R. Astron. Soc. **432**, 1862–1893 (2013) [doi:10.1093/mnras/stt644].

65. S. Kumar Panigrahi and A. Kumar Mishra, "Inner filter effect in fluorescence spectroscopy: As a problem and as a solution," J. Photochem. Photobiol. C Photochem. Rev. **41**, 100318 (2019) [doi:10.1016/j.jphotochemrev.2019.100318].

66. J. R. Lakowicz, "Quenching of Fluorescence," in Principles of Fluorescence Spectroscopy, J. R. Lakowicz, Ed., pp. 257–301, Springer US, Boston, MA (1983) [doi:10.1007/978-1-4615-7658-7_9].

67. M. H. Nguyen et al., "Toward fluorescence digital twins: multi-parameter experimental validation of fluorescence Monte Carlo simulations using solid phantoms," J. Biomed. Opt. **30**(S3), S34104, SPIE (2025) [doi:10.1117/1.JBO.30.S3.S34104].

68. L. Bai et al., "Super-stable cyanine@albumin fluorophore for enhanced NIR-II bioimaging," Theranostics **12**(10), 4536–4547 (2022) [doi:10.7150/thno.71443].

69. M. Ellmerer et al., "Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion," Am. J. Physiol.-Endocrinol. Metab. **278**(2), E352–E356 (2000) [doi:10.1152/ajpendo.2000.278.2.E352].

70.   T. Wang, L.-H. Zeng, and D.-L. Li, "A review on the methods for correcting the fluorescence inner-filter effect
of fluorescence spectrum," Appl. Spectrosc. Rev. **52**(10), 883–908, Taylor & Francis (2017)
[doi:10.1080/05704928.2017.1345758].

<u>Caption List</u>

Fig 1 The excitation-emission matrix (EEM) of a fluorophore is generated by **(a)** acquisition of fluorescence emission

spectra at various excitation wavelengths to produce the **(b)** three-dimensional EEM data set. The **(c)** EEM can be

used to obtain conventional **(d)** excitation and emission spectra by isolating data along a single wavelength on the

excitation or emission axis, respectively.

Fig 2 EEMs for samples with inherent scattering (3DP resin and albumin solutions) exhibit a scattering peak along

the excitation-emission line **(a)** which can be corrected through the use of the RLOESS smoothing algorithm to

result in the post-processed EEMs **(b)**.

Fig. 3 EEM and associated spectra for 1 µM ICG in DMSO: **(a)** Top-down plot of the acquired EEM. **(b)** Excitation

and emission spectra extracted from the EEM maxima. **(c)** Normalized excitation spectra at varying monitoring

emission wavelengths in the 800–840 nm range at 10 nm steps and **(d)** Normalized emission spectra at varying

excitation wavelengths in the 770–810 nm range at 10 nm steps.

Fig. 4: Concentration-dependent spectral effects for ICG in DMSO. **(a)** Plot of maximum fluorescence intensity vs.

concentration showing a consistent increase for the 0.03–3 µM range with a drop-off in intensity for the 10 µM

concentration. **(b)** Normalized fluorescence emission spectra at 785 nm excitation showing concentration-dependent

red shifts. **(c)** Absorbance spectra show consistent spectral features over the entire concentration while the **(d)**

excitation spectra show broadening and changes due to fluorescence re-absorption for the 3 µM and 10 µM

concentrations.

Fig. 5 EEM and associated spectra for 1 µM ICG in BSA solution (44 mg/mL). **(a)** Top-down plot of the acquired

EEM showing a 'rotation' of the central spectral feature indicating excitation-dependent spectral shifts. **(b)** Excitation

and emission spectra extracted from the EEM maxima. **(c)** Normalized excitation spectra at varying monitoring

emission wavelengths in the 800–840 nm range at 10 nm steps and **(d)** Normalized emission spectra at varying

excitation wavelengths in the 770–810 nm range at 10 nm steps.

Fig. 6 Fluorescence measurements of ICG in 5–100 mg/mL BSA solutions at 785 nm excitation: **(a)** relative excitation

spectra obtained at the monitored peak emission wavelength, and **(b)** relative emission spectra, both indicating no

significant changes in spectral characteristics across concentrations.

Fig. 7 EEM and associated spectra for 1 µM ICG in 3DP resin. **(a)** Top-down plot of the acquired EEM showing a

'rotation' of the central spectral feature indicating excitation-dependent spectral shifts. **(b)** Excitation and emission

spectra extracted from the EEM maxima. **(c)** Normalized excitation spectra at varying monitoring emission

wavelengths in the 800–840 nm range at 10 nm steps and **(d)** Normalized emission spectra at varying excitation

wavelengths in the 770–810 nm range at 10 nm steps.

Fig. 8 Spectral comparisons of 1 μM ICG in DMSO, BSA solution (44 mg/mL), and 3DP Resin: **(a)** Absorbance

spectra, (b) excitation spectra calculated from the EEM emission AUC, **(c,d)** fluorescence emission spectra at 760 nm

excitation, **(e,f)** fluorescence emission spectra at 785 nm excitation, and **(g,h)** fluorescence emission spectra at 805

nm excitation

Fig 9 Emission peak **(a-c)** and centroid **(d-f)** vs. excitation wavelength plot of 1 μM ICG in DMSO, BSA solution,

and 3DP resin: The peak emission wavelength for **(a)** ICG in DMSO showed no significant variation with excitation

wavelength while the **(b)** BSA solution and **(c)** 3DP resin data showed significant, non-linear, variations that include

REES. The emission centroid wavelength for **(d)** ICG in DMSO showed no significant variation with excitation

wavelength while the **(e)** BSA solution and **(f)** 3DP resin data showed significant, non-linear, variations that include

REES.

Table 1: Emission maxima, relative peak intensities, emission centroids, and relative integrated emission AUC

extracted from the EEM of 1 μM ICG in DMSO at excitation wavelengths of 770-810 nm (10 nm steps).

Table 2: Emission maxima, relative peak intensities, emission centroids, and relative integrated emission AUC

extracted from the EEM of 1 μM ICG in BSA solution (44 mg/mL) at excitation wavelengths of 770–810 nm (10 nm

steps).

Table 3: Emission maxima, relative peak intensities, emission centroids, and relative integrated emission AUC

extracted from the EEM of 1 μM ICG in 3DP Resin at excitation wavelengths of 770-810 nm (10 nm steps).

Table 4: Summarized data for the comparison of the spectral behavior of ICG in DMSO, BSA solution and 3DP

resin microenvironments. The integrated emission AUC is normalized to the counts of the DMSO solution emission

maxima at the 785 nm excitation.